Physician profile
Steven Warnock
NPI 1457337594
$7,768.48
in general payments reported to CMS, 2019-2025
14 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,536 · 2020: $472 · 2021: $397 · 2022: $106 · 2023: $388 · 2024: $492 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,283.95 | 2019-2022 | |
| Abbvie INC. | $716.78 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Mentor Worldwide LLC | $354.28 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Integra Lifesciences Corporation | $74.23 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Motiva USA, LLC | $73.59 | 2024-2025 | |
| Sientra, INC. | $66.84 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $42.05 | 2024-2025 | Exparel, Zilretta, Iovera |
| Innovation Technologies INC | $33.06 | 2025 | Irrisept |
| Tela Bio, INC. | $32.51 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Apyx Medical Corporation | $26.52 | 2020 | |
| Kci USA, INC. | $22.99 | 2021 | |
| Smith+Nephew, INC. | $15.73 | 2021 | |
| Bard Peripheral Vascular, INC. | $13.66 | 2021 | |
| Ethicon US, LLC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.